The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs to determine the Efficacy in Treatment of Advanced Cancers with a Known Molecular Profile

Status

Not yet recruiting

Phases

Phase 2

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-517478-68-01

Acronym

FINPROVE

Enrollment

250

Registered

2024-11-06

Start date

Unknown

Completion date

Unknown

Last updated

2024-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Advanced Cancer

Brief summary

Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD)

Detailed description

Duration of treatment on study (time on drug), Treatment-related grade ≥3 and serious adverse events, Best overall response (defined as patients by CR, PR, SD), Progression free survival, Overall survival

Interventions

DRUGPemazyre 4.5 mg tablets

DRUGPhesgo 600 mg/600 mg solution for injection

DRUGErivedge 150 mg hard capsules

DRUGErleada 60 mg film-coated tablets

DRUGVerzenios 50 mg film-coated tablets

DRUGMekinist 0.5 mg film-coated tablets

DRUGPhesgo 1200 mg/600 mg solution for injection

DRUGTecentriq 840 mg concentrate for solution for infusion

DRUGTafinlar 75 mg hard capsules

DRUGCotellic 20 mg film-coated tablets

DRUGRozlytrek 200 mg hard capsules

DRUGLynparza 150 mg film-coated tablets

DRUGMekinist 2 mg film-coated tablets

DRUGAlecensa 150 mg hard capsules

DRUGStivarga 40 mg film-coated tablets

DRUGZelboraf 240 mg film-coated tablets

DRUGTEPMETKO 225 mg film-coated tablets

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Disease control rate at 16 weeks after treatment initiation (defined as patients by CR, PR, SD)	—

Secondary

Measure	Time frame
Duration of treatment on study (time on drug), Treatment-related grade ≥3 and serious adverse events, Best overall response (defined as patients by CR, PR, SD), Progression free survival, Overall survival	—

Countries

Finland

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026